

September 2021; United States Patent 10,287,350 (HHS Reference E-042-2014-0-US-15), issued 14 May 2019; Hong Kong Patent HK 1234420 (HHS Reference E-042-2014-0-HK-16), issued 4 June 2021; United States Patent 11,236,161 (HHS Reference E-042-2014-0-US-17), issued 1 February 2022; New Zealand Patent Application 764530 (HHS Reference E-042-2014-0-NZ-18), filed 19 May 2020; European Patent Application 20197459.9 (HHS Reference E-042-2014-0-EP-25), filed 22 September 2020; Australian Patent Application 2020267211 (HHS Reference E-042-2014-0-AU-26), filed 11 November 2020; Japanese Patent 7004470 (HHS Reference E-042-2014-0-JP-27), issued 6 January 2022; Mexican Patent Application MX/a/2021/006239 (HHS Reference E-042-2014-0-MX-28), filed 27 May 2021; Israeli Patent Application 283423 (HHS Reference E-042-2014-0-IL-29), filed 25 May 2021; Hong Kong Patent Application 42021038427.7 (HHS Reference E-042-2014-0-HK-30), filed 8 September 2021; United States Patent Application 17/557,845 (HHS Reference E-042-2014-0-US-31), filed 21 December 2021; Japanese Patent Application 2021-215427 (HHS Reference E-042-2014-0-JP-32), filed 29 December 2021; United States Patent Application 17/696,249 (HHS Reference E-042-2014-0-US-33), filed 16 March 2022; Israeli Patent Application 291292 (HHS Reference E-042-2014-0-IL-34), filed 13 March 2022, and U.S. and foreign patent applications claiming priority to the aforementioned applications.

The patent rights in these inventions have been assigned and/or exclusively licensed to the government of the United States of America.

The license to be granted may be worldwide, and may be limited to the following field of use:

“The commercial development, production, and sale of a monospecific chimeric antigen receptor (CAR)-based immunotherapy using T lymphocytes transfected *in vivo* using non-viral, synthetic nanoparticle-based systems comprised of lipids, polymers and/or lipopolymers that deliver a nucleic acid cargo that expresses an anti-CD19 CAR having:

(1) the CDR polypeptide sequences of the anti-CD19 antibody known as Hu19; and

(2) a T cell signaling domain; for the treatment or prevention of CD19-expressing cancers.

The Licensed Field of Use explicitly excludes the development of a bispecific or bicistronic CAR and the

use of viral-based nucleic acid systems or vectors to express the CAR.”

CD19 is a cell surface protein that is expressed on a number of types of cancer cells, including various lymphomas and leukemias. Although there are several therapies available for patients with these types of cancers, many patients still either do not respond to these therapies or experience disease relapse and require additional lines of therapy. As a result, there continues to be an unmet patient need. The development of a new anti-CD19 CAR-based therapy can potentially meet some or all of these needs. As a result, the development of a new therapeutic option targeting CD19-expressing cancers will benefit public health by providing an effective treatment for patients that might otherwise have no options.

This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing, and the prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Cancer Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.

In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.

License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.

Dated: July 21, 2022.

Richard U. Rodriguez,

Associate Director, Technology Transfer Center, National Cancer Institute.

[FR Doc. 2022-16056 Filed 7-26-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as

amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Neurological Disorders and Stroke Special Emphasis Panel; ALS Expanded Access Program.

Date: August 17, 2022.

Time: 9:00 a.m. to 2:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 (Virtual Meeting).

Contact Person: W. Ernest Lyons, Ph.D., Scientific Review Administrator, Scientific Review Branch, Division of Extramural Activities, NINDS/NIH/DHHS, NSC, 6001 Executive Boulevard, Suite 3208, MSC 9529, Bethesda, MD 20892-9529, 301-496-4056, lyonse@ninds.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, Clinical Research Related to Neurological Disorders; 93.854, Biological Basis Research in the Neurosciences, National Institutes of Health, HHS)

Dated: July 20, 2022.

Tyeshia M. Roberson-Curtis,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2022-16046 Filed 7-26-22; 8:45 am]

BILLING CODE 4140-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Eye Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which